Patients with rheumatoid arthritis who initiated treatment with sarilumab experienced higher reductions in A1C level, regardless of their diabetes status, compared with those received placebo or adalimumab. The findings in the journal Arthritis Research & Therapy were based on data from a post-hoc analysis of three phase III studies.
Study: Sarilumab tied to higher A1C reduction in RA
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.